Inventor · disambiguated record
Mark Anderson
Also filed as: ANDERSON MARK · ANDERSON MARK G
10 granted patents·12 pending applications·56 citations·filing 2007–2023
87Inventor score
Top patents by PatentIndex Score
22 records- 0192US10383948B2Anti-cMet antibody drug conjugates and methods for their useABBVIE INC·Filed 2018·Granted Aug 20, 2019·10 cites·12 claims
- 0289US11633497B2Anti-c-Met antibody drug conjugatesABBVIE INC·Filed 2022·Granted Apr 25, 2023·1 cites·8 claims
- 0389US10662235B2Cysteine engineered fibronectin type III domain binding moleculesJANSSEN BIOTECH INC·Filed 2017·Granted May 26, 2020·4 cites·15 claims
- 0489US9725515B2Prolactin receptor binding proteins and uses thereofABBVIE INC·Filed 2013·Granted Aug 8, 2017·10 cites·50 claims
- 0583US9725497B2EGFR and C-Met fibronectin type III domain binding moleculesJANSSEN BIOTECH INC·Filed 2013·Granted Aug 8, 2017·5 cites·13 claims
- 0683US8624027B2Combination therapy for treating cancer and diagnostic assays for use thereinSHAH OMAR JAMEEL·Filed 2009·Granted Jan 7, 2014·24 cites·10 claims
- 0779US10112999B2Anti-PRLR antibody-drug conjugates (ADC) and uses thereofABBVIE INC·Filed 2018·Granted Oct 30, 2018·1 cites·11 claims
- 0874US12304939B2EGFR and C-met fibronectin type III domain binding moleculesJANSSEN BIOTECH INC·Filed 2021·Granted May 20, 2025·0 cites·8 claims
- 0973US2023372519A1Anti-c-met antibody drug conjugatesABBVIE INC·Filed 2023·Application pending·0 cites
- 1072US10184003B2Prolactin receptor binding proteins and uses thereofABBVIE INC·Filed 2016·Granted Jan 22, 2019·1 cites·30 claims
- 1165US10954284B2EGFR and c-Met fibronectin type III domain binding moleculesJANSSEN BIOTECH INC·Filed 2017·Granted Mar 23, 2021·0 cites·6 claims
- 1265US2019010237A1Anti-prlr antibody-drug conjugates (adc) and uses thereofABBVIE INC·Filed 2018·Application pending·0 cites
- 1365US2021312797A9Prolactin receptor binding proteins and uses thereofABBVIE INC·Filed 2020·Application pending·0 cites
- 1463US2021061916A1Anti-prlr antibody-drug conjugates (adc) and uses thereofABBVIE INC·Filed 2020·Application pending·0 cites
- 1558US2020325210A1Cysteine engineered fibronectin type iii domain binding moleculesJANSSEN BIOTECH INC·Filed 2020·Application pending·0 cites
- 1658US2019153110A1Prolactin receptor binding proteins and uses thereofABBVIE INC·Filed 2018·Application pending·0 cites
- 1758US2017348429A1ANTI-cMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USEABBVIE BIOTHERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 1857US2010028889A1Companion diagnostic assays for cancer therapyABBOTT LAB·Filed 2009·Application pending·0 cites
- 1951US2008199873A1Companion diagnostic assays for cancer therapyANDERSON MARK G·Filed 2007·Application pending·0 cites
- 2049US2020297863A1Anti-egfr antibody drug conjugates (adc) and uses thereofABBVIE INC·Filed 2018·Application pending·0 cites
- 2149US2020188525A1Anti-egfr antibody drug conjugates (adc) and uses thereofABBVIE INC·Filed 2018·Application pending·0 cites
- 2238US2010196907A1Markers to predict and monitor response to aurora kinase b inhibitor therapyABBOTT LAB·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Mark Anderson files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →